Skip Navigation


Rheumatology Advance Access originally published online on May 8, 2009
Rheumatology 2009 48(7):721-726; doi:10.1093/rheumatology/kep099
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
48/7/721    most recent
kep099v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Jia, J.
Right arrow Articles by Zhu, P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jia, J.
Right arrow Articles by Zhu, P.
Related Collections
Right arrow Experimental Arthritis
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Inhibitory effect of CD147/HAb18 monoclonal antibody on cartilage erosion and synovitis in the SCID mouse model for rheumatoid arthritis

Junfeng Jia1, Conghua Wang1, Zhanguo Shi1, Jingkang Zhao1, Yun Jia1, Zheng Zhao-Hui1, Xiaoyan Li1, Zhinan Chen2,* and Ping Zhu1,*

1Department of Clinical Immunology, State Key Discipline of Cell Biology, Xijing Hospital, Fourth Military Medical University and 2Department of Cell Biology/Cell Engineering Research Centre, Cancer Biology of State Key Laboratory, State Key Discipline of Cell Biology, Fourth Military Medical University, Xi’an, Shaanxi Province, P. R. of China.

Correspondence to: Ping Zhu, Department of Clinical Immunology, State Key Discipline of Cell Biology, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, Shaanxi Province, P.R. of China. E-mail: zhuping{at}fmmu.edu.cn


  Abstract

Objective. To explore the therapeutic potential of CD147/HAb18 mAb in the treatment of RA in severe combined immunodeficiency (SCID) mice engrafted with human cartilage and rheumatoid synovium tissue (SCID-HuRAg).

Methods. SCID-HuRAg mice were treated separately with CD147/HAb18 mAb, anti-TNF-{alpha} mAb or a combination of both. The mice in control group were treated with anti-Japanese encephalitis virus mAb. The volume of engrafts was measured and the number of inflammatory cells and cartilage erosion score were examined. Expression of MMP-2, -3 and -9 was determined by immunohistochemistry. Human inflammatory cytokine levels in mouse sera were assessed using cytometric bead array kit.

Results. The volume of engrafts decreased significantly in SCID-HuRAg mice treated separately with anti-CD147 mAb or anti-TNF-{alpha} mAb, and in the mice treated with anti-CD147 mAb plus anti-TNF-{alpha} mAb (P < 0.05). Significant reduction was observed in cartilage erosion score in anti-CD147 treatment group and combined treatment group (P < 0.05). Immunohistochemical analysis showed that expression of MMP-2, -3 and -9 was lower in the anti-CD147 treatment group and combined treatment group than in the control mAb group (P < 0.05). Moreover, the level of TNF-{alpha}, IL-6 and -8 in CD147 mAb group showed a significant decrease compared with that of the control mAb group (P < 0.05).

Conclusions. CD147/HAb18 mAb can reduce cartilage erosion and synovitis by inhibition of the MMPs and reduction of inflammatory cytokines in SCID-HuRAg mice, which suggests that CD147/HAb18 mAb is a promising treatment option for RA patients.

KEY WORDS: Rheumatoid arthritis, CD147, HAb18, Inflammation, SCID-HuRAg mouse, Pathology

*Ping Zhu and Zhinan Chen equally contributed to this work.

Submitted 27 October 2008; revised version accepted 26 March 2009.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.